Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAI003
- Development stage
- Preclinical
- Lead developer
- Hangzhou Nain Biotechnology
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NAI003 is a preclinical small-molecule drug candidate developed by Hangzhou Nain Biotechnology for the treatment of solid tumors. It targets the PDIA6/IRE1 signaling axis, which is a key component of the unfolded protein response (UPR) pathway. PDIA6 (Protein Disulfide Isomerase Family A Member 6) is an endoplasmic reticulum-resident chaperone that interacts with and regulates the activity of IRE1 (Inositol-requiring enzyme 1), a primary sensor of ER stress. By disrupting this pathway, NAI003 aims to impair the ability of cancer cells to manage protein folding stress, thereby inducing apoptosis and inhibiting tumor growth in stressful microenvironments.
02
Targets
EF-Tu (Mitochondrial elongation factor TUFM)ERN1 (Inositol-requiring enzyme 1 alpha)PDIA6 (Protein disulfide-isomerase A6)
Beyond the preview
Go deeper on NAI003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAI003.